行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

2.630
-0.050
-1.87%
盘后: 2.600 -0.03 -1.14% 17:43 04/20 EDT
开盘
2.580
昨收
2.680
最高
2.650
最低
2.529
成交量
39.04万
成交额
--
52周最高
4.230
52周最低
1.400
市值
1.13亿
市盈率(TTM)
-1.4395
分时
5日
1月
3月
1年
5年
BioLineRx将出席2021年美国癌症研究协会年会
ioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has presented a poster at the AACR Annual Meeting, which is being
Benzinga · 5天前
Biolinerx(BLRX)获得美信集团的买入评级
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Biolinerx (BLRX), with a price target of $5.00. The company's
SmarterAnalyst · 02/26 13:28
细价股在2月激增,现在有3只便宜股值得关注
Penny Stocks · 02/24 21:10
Biolinerx(BLRX)从Oppenheimer获得买入评级
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx (BLRX), with a price target of $10.00. The
SmarterAnalyst · 02/24 10:02
HC Wainwright维持对Biolinerx(BLRX)的买入
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX) yesterday and set a price target of $19.00. The company's shares
SmarterAnalyst · 02/24 07:15
HC Wainwright&Co将DJ BioLine RX的价格目标从22.00美元下调至19.00美元/股。
Dow Jones · 02/23 16:34
HC Wainwright&Co将DJ BioLine RX维持在“买入”评级。
Dow Jones · 02/23 16:34
每日生物技术动向:Dynavax偷猎GSK疫苗执行机构,KalVista跳出数据读取流程,概念发布负面的预告
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解BLRX最新的财务预测,通过BLRX每股收益,每股净资产,每股现金流等数据分析BioLine RX近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测BLRX价格均价为11.33,最高价位19.00,最低价为5.00。
EPS
机构持股
总机构数: 41
机构持股: 208.37万
持股比例: 4.87%
总股本: 4,279.23万
类型机构数股数
增持
3
3.57万
建仓
8
57.96万
减持
5
3.75万
平仓
5
280.63万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.29%
制药与医学研究
+0.33%
高管信息
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Chief Scientific Officer
Merril Gersten
Vice President
Ella Sorani
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
David Malek
Vice President - Business Development
Hillit Mannor Shachar
Director
Michael Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
General Manager
Leah Klapper
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
暂无数据
BLRX 简况
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

微牛提供BioLine RX Ltd(NASDAQ-BLRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BLRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BLRX股票基本功能。